New drug information

- **AirDuo™ RespiClick® (fluticasone propionate/salmeterol):** The Food and Drug Administration (FDA) approved Teva's AirDuo for patients aged 12 years and older with asthma. AirDuo contains the same active ingredients as GlaxoSmithKline's Advair®, but is not directly interchangeable due to slightly different strengths approved. The approved strengths of AirDuo are: 55/14 mcg, 113/14 mcg and 232/14 mcg, administered as one inhalation twice daily. In addition, AirDuo is only approved in asthma patients; Advair is approved for both asthma and chronic obstructive pulmonary disease (COPD). RespiClick is Teva’s breath-activated device.

- **ArmonAir™ RespiClick® (fluticasone propionate):** The FDA approved Teva’s ArmonAir for the treatment of asthma in patients aged 12 years and older. ArmonAir contains the same active ingredient as in GlaxoSmithKline’s Flovent®, but is not directly interchangeable as ArmonAir was approved in different strengths. The approved strengths of ArmonAir are: 55 mcg, 113 mcg, and 232 mcg, administered as one inhalation twice daily.

New generics

- **Cordran (flurandrenolide 0.05% ointment):** Teligent has launched the first generic version of Aqua Pharmaceutical’s Cordran ointment for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.